Research Highlights

Since its inception, the Vancouver Prostate Centre’s research activities have led to valuable new insights, treatments, and intellectual property:

  • We were instrumental in establishing the use of Intermittent Androgen Ablation Therapy as a standard treatment modality for prostate cancer
  • In 2015, the Centre developed a potential new therapeutic that is designed to outsmart cancer and inhibit tumour growth by disabling the androgen receptor where it binds to a specific part of the DNA that is not prone to mutation, opening the possibility of designing drugs that could be effective for a long time
    • The drug candidate was developed using new CADD (computer aided drug design), a computer technology that evaluates a database of millions of different molecules to identify a handful which may work well as possible treatments
  • My Precision Oncology Program (MyPOP), made possible by new infrastructural investment from the Canadian Foundation for Innovation and a generous donation by a private donor, allows for the routine linking of genomic sequencing data with real-time clinical decision making
  • Our annual knowledge output averages 80 peer-reviewed publications and 75 presentations at conferences
  • Since 2008, our Centre has been awarded over $80 million in peer-reviewed research grants from regional, national and international agencies
  • Since 2008 we have initiated 109 new Clinical Trials enrolling 1,721 patients
  • We have a strong record of recruitment of senior staff and faculty promotions
  • The Centre currently had 44 post-doctoral fellows, 31 Ph.D. students and 21 Masters students
  • Since 2008 we have negotiated 52 new contract research agreements with pharmaceutical and biotech companies including Pfizer, Takeda and AstraZeneca
  • Intellectual Property Activities since 2008 include
    •  259 patent filed/issued
    •  9 Licensing Agreements of IP with Industry (8 drug, 1 Biomarker)
  • Discoveries at our Centre have created four biotech companies:
    • OncoGeneX
      • OGX-011 : in advanced Phase III studies
      • OGX-427 : in multiple Phase II studies
    • Aquinox 
      • shp inhibitors, in Phase II studies
    • Andronex
      • novel AR ligands
    • Sitka Biopharma
      • Formulations of Paclitaxel for bladder cancer

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

BMO Vancouver Marathon, May 7: Prostate Cancer Foundation BC fundraiser

Prostate Cancer Foundation BC has a fundraising page for participants in the BMO Vancouver Marathon on May 7th.  You can make a donation by clicking here, or contact PCF-BC for more information of how to help at prostatebceventsattelus [dot] net.

Employment

Work at the Vancouver Prostate Centre

Monday, January 30, 2017

Dr. Amina Zoubeidi leads identification of gene linked to growth of aggressive neuroendocrine prostate cancer (NEPC)

DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.